BioSyent (RX.V) Aktie Kurs
BioSyent Kurs
Omsætningen er vokset med 19,3 % om året de seneste 19 år til 43,05 Mio. CAD. Indtjening pr. aktie er vokset med 18,6 % om året de seneste 19 år. BioSyents nettoavance ligger på 20,9 %, ned fra 21,9 % for flere år siden. BioSyent har i øjeblikket et direkteafkast på omkring 1,18 %. Udlodningsandelen er omkring 25 % af indtjeningen. Udbyttet er vokset med 71,0 % om året de seneste 3 år. Analytikernes mediankursmål er 16,83 CAD, hvilket er under den aktuelle kurs med 1,0 %. Af 7 analytikere anbefaler 6 køb — den samlede vurdering er Køb.
BioSyent aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
BioSyent aktie og aktieanalyse
Hyppigt stillede spørgsmål om BioSyent-aktien
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 16,83 CAD for BioSyent-aktien (median: 16,83 CAD), svarende til -1,0 % i forhold til seneste kurs. Konsensus bygger på 7 analytikervurderinger.
7 analytikere vurderer i øjeblikket BioSyent-aktien: 6 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at BioSyent genererer omsætning på 73,20 Mio. CAD og indtjening pr. aktie på 1,05 CAD.
Omregnet til den aktuelle valutakurs handles BioSyent-aktien til 10,88 EUR (17,00 CAD).
BioSyent-aktien (RX.V) er noteret på 2 børser, herunder: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
forventet-omsætningen for BioSyent er 73,20 Mio. CAD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for BioSyent er 11,81 Mio. CAD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for BioSyent er i øjeblikket 16,21. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af BioSyent-aktien.
Pris-til-salgs-forholdet (P/S) for BioSyent er i øjeblikket 2,62. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for BioSyent-aktien.
AlleAktien-kvalitetsscore for BioSyent er 8/10.
ISIN for BioSyent er CA0906901081. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for BioSyent er A1J6DY. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for BioSyent er RX.V. Tickersymbolet bruges til at handle BioSyent-aktier på børsen.
BioSyent aktie
BioSyent Peer Group
BioSyent Ticker
BioSyent FIGI
Alle fundamentale data om BioSyent i deep dive
Vores aktieanalyse af BioSyent-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos BioSyent. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: